Operation of Korea Pavilion, IR Programs, and Korea Night
"Enhancing the Value of the K-Pharma and Bio Brand"

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (hereinafter referred to as the Association) announced on the 12th that it is participating in the bio industry event 'BIO CHINA 2026,' held in Suzhou, China, from March 12 to 14, to support Korean pharmaceutical and bio companies in entering the Chinese market and discovering global partnership opportunities.

At the opening ceremony of BIO CHINA 2026 held on the 12th (local time) at Suzhou International Expo Center in China, Noh Yeon-hong, Association President (second from left), is performing the ceremony as the representative of Korea. Korea Pharmaceutical and Bio-Pharma Manufacturers Association

At the opening ceremony of BIO CHINA 2026 held on the 12th (local time) at Suzhou International Expo Center in China, Noh Yeon-hong, Association President (second from left), is performing the ceremony as the representative of Korea. Korea Pharmaceutical and Bio-Pharma Manufacturers Association

View original image

BIO CHINA is a pharmaceutical and bio exhibition and convention event organized by Enmore Bio, a Chinese bio industry platform company. About 30,000 participants from more than 40 countries, including major Chinese pharmaceutical companies, global corporations, investors, and research institutions, are attending. During the event, more than 250 forums and over 400 company exhibitions will be held, with more than 5,000 business meetings scheduled.


This year, the Association launched the 'BIO CHINA Participation Support Program' for the first time. Through operating the Korea Pavilion, promoting companies, hosting IR programs for investment attraction, and organizing networking events, the Association aims to expand opportunities for technological collaboration and investment for Korean companies.


Twenty-one domestic pharmaceutical and bio companies are participating in the Korea Pavilion, which is jointly organized by the Korea Trade-Investment Promotion Agency (KOTRA) and the Korea Health Industry Development Institute. These companies will introduce their pipelines and core technologies. Among them, five companies will be provided with separate promotional tables.


At the BioBD Roadshow on the 13th, six Korean companies will give presentations to global pharmaceutical firms and investors on topics such as antibody-drug conjugate (ADC) linker platforms and artificial intelligence-based therapeutic development technologies.


On the same day, about 180 representatives from Korean and Chinese pharmaceutical and bio companies and institutions will attend the networking event 'Korea Night' to discuss opportunities for technological cooperation and joint business ventures.


Prior to the event, the Association visited local bio clusters, including the Wuxi Innovation Hub Campus (iCampus) and Suzhou Industrial Park (SIP) BioBay, to assess their operations and discuss avenues for cooperation.



Noh Yeonhong, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, said, "Through this initiative, we will expand opportunities for Korean companies to enter the Chinese market and pursue global cooperation."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing